On CNBC's "Cramer's Mad Dash" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said the biotech company's management almost always provides conservative guidance.
"This company has a lot of earnings power. They've got a lot of new drugs," he added.
The stock will likely be a down a couple of percentage points on Friday. If so, that's when investors should consider buying, Cramer concluded.
-- Written by Bret Kenwell in Petoskey, Mich.